Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Management of Recurrent Pterygium to Prevent Visual Impairment (REPEAT)
2015-003217-20Phase 4Completed
- Sponsor
- University of Nottingham
- Start
- Feb 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of bevacizumab and fluorouracil in pterygium, sponsored by University of Nottingham. Primary endpoint: Arrest of progression of the fibrovascular tissue. Started Feb 2016; status: completed.
02
Drugs
bevacizumabfluorouracil
03
Conditions
pterygium
Beyond the preview
Go deeper on 2015-003217-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003217-20.